Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Rituxan Prescribers: Hematologists (US)(?)

Council Members in this Study Group: 46

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Ben Ebrahimi, MD
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi

Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...

Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research Center

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

Eric Jacobsen, MD
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School

Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.

Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD
Medical Director of Hematology
Big Sky Oncology

Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...

Michael Flamm, M.D., Ph.D.
Director of the Oupatient Hematology
THE NEW YORK-PRESBYTERIAN HOSPITAL

Michael Flamm, MD, PhD, is the Director of the Outpatient Hematology Clinic at the Columbia Presbyterian campus of the New York Presbyterian Hospital. He has expertise in the treatment of sickle cell anemia and paroxysmal nocturnal hemoglobinuria, and he also treats patients with hematologic malignancies...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Bcl-2 apoptosis inhibition: The next "best" thing? | 08-29-2008
Author: GLG Expert Contributor

Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!

So Much for GVAX.... for now? | 08-29-2008
Author: GLG Expert Contributor

No reason for the increased mortality vs Chemo alone was identified. Cell Genesys is looking into where to go now.

Velcade in myeloma 1st line. Am I s?urprised | 08-29-2008
Author: GLG Expert Contributor

Velcade + classic Melphalan/ Prednisone  (MP) is better than MP alone. No surprise

Amgen's long awaited product to treat chronic ITP will be well receive. | 08-25-2008
Analysis of: Amgen Blood-Disorder Drug Gains Clearance | online.wsj.com
Author: GLG Expert Contributor

Chronic ITP is not all that uncommon and becomes a quality of life issue with chronic steroid use as well as agents that are normaly used in neoplasia and even derivatives of male hormones.

Artificial red blood cells (RBC'S): preliminary but very promising. | 08-21-2008
Analysis of: Scientists Find Way to Create Red Blood Cells | online.wsj.com
Author: GLG Expert Contributor

Advanced Cell Technology in Worcester, Mass., the University of Illinois at Chicago and the Mayo Clinic in Rochester, Minn. scientists say they've found an efficient way to make red blood cells from human embryonic stem cells. Impreesive!

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*
  • Government/Military Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Director
  • Owner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-08-30T05:45:15.877